Catalent Collaborates with MGB Biopharma to Provide Accelerated Formulation and Supply Services for Phase 2 Clinical Trial Materials SOMERSET, N.J. – April 25, 2019 — Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it welcomed the commencement of Phase 2 clinical […]
Read MoreCategory: blog
Catalent Invests $14 Million at its Eberbach, Germany Softgel Facility
Catalent Invests $14 Million at its Eberbach, Germany Softgel Facility Expands Production and Packaging Capabilities, and Infrastructure in Response to Increasing Demand for Integrated Turnkey Services SOMERSET, N.J. – April 23, 2019 — Catalent, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced […]
Read MoreCatalent Celebrates Opening of Second Shanghai Facility to Optimize Global and Local Clinical Supply Solutions for China
Catalent Celebrates Opening of Second Shanghai Facility to Optimize Global and Local Clinical Supply Solutions for China SOMERSET, N.J. – April 11, 2019 — Catalent Pharma Solutions, a global leader in clinical supply services, today announced the completion of its new, 30,000-square-foot clinical supply facility in Shanghai, China. The event was marked with an official […]
Read MoreCatalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth SOMERSET, N.J. and BALTIMORE, Md. – April 15, 2019 – Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies […]
Read MoreCatalent Expands OptiMelt® Hot Melt Extrusion Capabilities at Somerset Drug Development Center of Excellence
Catalent Expands OptiMelt® Hot Melt Extrusion Capabilities at Somerset Drug Development Center of Excellence SOMERSET, N.J. – April 4, 2019 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has invested a further $5 million at the company’s […]
Read MoreTriphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology Toronto, Ontario, and Somerset, N.J. – April 1, 2019 – Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider […]
Read MoreINTUITIVE BIOTECHNOLOGIES OFFERS NOVEL, COST EFFICIENT, AND TIME SAVING ALTERNATIVES TO ANIMAL TESTING FOR THE HEALTHCARE INDUSTRY
PRESS RELEASE DATE: 19March2019 INTUITIVE BIOTECHNOLOGIES OFFERS NOVEL, COST EFFICIENT, AND TIME SAVING ALTERNATIVES TO ANIMAL TESTING FOR THE HEALTHCARE INDUSTRY INTUITIVE BIOTECHNOLOGIES (IBT) is an innovative startup focusing on analytical test-ing of biological samples. It is located at the Pasadena Bio Collaborative Incubator (PBC) in Pasadena, CA. Our company is developing in vitro methodologies […]
Read MoreBlog Post by Rapid Novor regarding Mega Pharma Mergers
With the mega pharma mergers that keep cropping up and are likely to continue into the future, what is the impact felt by CROs? What normally happens after merging of two big pharma companies is always a round of laying off and re-organization. Also, the combined pipelines would be trimmed as a result of the […]
Read More